ND0701 is an apomorphine-based product candidate designed to offer a next-generation alternative to the continuously administered apomorphine product currently approved and sold outside the United States. NeuroDerm is working to significantly improve local tolerability and safety, the biggest drawback of the current apomorphine product, and allow a much lower daily administration volume.
ND0701 will be used by a subset of patients who suffer from severe Parkinson’s disease and do not respond well to LD/CD. ND0701 will be administered via a patch pump.
ND0701 is currently in Phase 1 clinical studies.